Nu Skin Enterprises (NUS) 28th Annual ICR Conference 2026 summary
Event summary combining transcript, slides, and related documents.
28th Annual ICR Conference 2026 summary
12 Jan, 2026Industry trends and innovation
Wellness industry projected to reach $1 trillion by 2030, with supplements at $480 billion and wearables at $80 billion.
Increasing consumer demand for personalized health data and biomarker measurement is driving innovation.
IoT-connected beauty and wellness devices are central to delivering personalized solutions.
AI and proprietary algorithms are being leveraged to interpret large health datasets for tailored recommendations.
The company is recognized as the world's largest beauty and wellness device systems brand.
Product development and technology
Prysm iO integrates biophotonic scanning and AI to provide proprietary nutritional health scores.
Over 26 million scans from 10 million people in 50 countries have built a vast nutritional health database.
Devices are complex, IoT-enabled, and designed for in-home use, supporting a subscription-based model.
Product solutions are guaranteed to improve nutritional health scores, differentiating from other wearables.
Focus on bioabsorption and effective supplementation to address gaps in the $480 billion supplement market.
Market expansion and strategy
Latin America is the fastest-growing segment, with a scalable and profitable model adapted for local needs.
India is targeted for mid- to long-term growth, with a digital-first approach and local partnerships.
Lessons from Latin America and India will inform expansion into Southeast Asia, Eastern Europe, and smaller Chinese cities.
Regional revenue distribution is now balanced, reducing risk and increasing resilience.
Continued focus on diversification and leveraging digital strategies for emerging markets.
Latest events from Nu Skin Enterprises
- 2025 EPS rose 51% despite revenue declines; 2026 growth expected from new launches and India expansion.NUS
Q4 202512 Feb 2026 - Q2 revenue fell 12.2% to $439.1M, with Rhyz up 32% and a $118.3M net loss on restructuring.NUS
Q2 20241 Feb 2026 - Q3 revenue fell 13.8%–14% YOY to $430.1M; Rhyz segments grew over 20% amid core declines.NUS
Q3 202415 Jan 2026 - Q4 revenue and EPS beat guidance but fell year-over-year; 2025 outlook remains cautious.NUS
Q4 202416 Dec 2025 - Proxy covers director elections, pay, incentive plan, auditor, and ESG progress.NUS
Proxy Filing2 Dec 2025 - Director elections, executive pay, incentive plan, and auditor ratification headline the 2025 meeting.NUS
Proxy Filing2 Dec 2025 - Q2 EPS surged to $0.43 as cost controls and Rhyz growth offset broad revenue declines.NUS
Q2 202523 Nov 2025 - Q1 revenue at $364.5M, adjusted EPS $0.23, Mavely sale lifts net income despite broad declines.NUS
Q1 202520 Nov 2025 - Q3 revenue fell 15.3% but EPS doubled; Prism iO and India launches to drive future growth.NUS
Q3 202515 Nov 2025